| pubmed-article:21291499 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0022646 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0024432 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0035126 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0041904 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0332448 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C1415619 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:21291499 | lifeskim:mentions | umls-concept:C0059438 | lld:lifeskim |
| pubmed-article:21291499 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:21291499 | pubmed:dateCreated | 2011-4-5 | lld:pubmed |
| pubmed-article:21291499 | pubmed:abstractText | Epigallocatechin-3-gallate (EGCG) shows diverse chemical and biological activities. We investigated the effects of EGCG in a rat renal ischemia reperfusion (I/R) injury model. Sprague-Dawley rats received intraperitoneal injection of 50 mg/kg EGCG 48 h, 24 h, and 30 min prior to I/R injury. The animals were subjected to left renal occlusion for 45 min. EGCG treatment suppressed the peak in serum creatinine. EGCG-treated kidneys showed significantly less tubular damage and a decreased number of apoptotic cells. The I/R-induced elevation in the renal MDA level was significantly decreased in the EGCG group. Reverse-transcriptase polymerase chain reaction showed that EGCG significantly decreased the expression of MHC class II, TLR2, TLR4, MCP-1, IL-18, TGF-?1, procollagen Ia1, TIMP-1, and Kim-1. ED-1 staining showed reduced macrophage infiltration and ?-SMA staining revealed less interstitial expression. Heme oxygenase-1 (HO-1) expression in I/R kidneys was upregulated in the EGCG group based on the results of both RT-PCR and Western blotting analysis. Blockade of HO-1 gene induction by SnPP increased renal tubular damage and macrophage infiltration. These findings suggest that EGCG protects the kidneys against I/R injury by reducing macrophage infiltration and decreasing renal fibrosis. These beneficial effects may be mediated, in part, by augmentation of the HO-1 gene. | lld:pubmed |
| pubmed-article:21291499 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21291499 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21291499 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21291499 | pubmed:month | May | lld:pubmed |
| pubmed-article:21291499 | pubmed:issn | 1432-2277 | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:IsakaYoshitak... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:TakaharaShiro... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:NonomuraNorio... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:MatsumuraKazu... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:HyonSuong-Hyu... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:IchimaruNaots... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:YazawaKojiK | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:AbeToyofumiT | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:OkumiMasayosh... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:TsutaharaKoic... | lld:pubmed |
| pubmed-article:21291499 | pubmed:author | pubmed-author:KakutaYoichiY | lld:pubmed |
| pubmed-article:21291499 | pubmed:copyrightInfo | © 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation. | lld:pubmed |
| pubmed-article:21291499 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21291499 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:21291499 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21291499 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21291499 | pubmed:pagination | 514-22 | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:meshHeading | pubmed-meshheading:21291499... | lld:pubmed |
| pubmed-article:21291499 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21291499 | pubmed:articleTitle | Epigallocatechin-3-gallate protects kidneys from ischemia reperfusion injury by HO-1 upregulation and inhibition of macrophage infiltration. | lld:pubmed |
| pubmed-article:21291499 | pubmed:affiliation | Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. | lld:pubmed |
| pubmed-article:21291499 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21291499 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:24451 | entrezgene:pubmed | pubmed-article:21291499 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21291499 | lld:entrezgene |
